Fig. 1

LQF relieves ventricular remodeling after AMI in vivo. A Ventricular remodeling was constructed in Wistar rats and randomly divided into 4 groups (for all groups, n = 6). Rats were administered by gavage with LQF (dry powder, 315 mg/kg, equal to clinical dose for human) or BNZ (10 mg/kg) for 4 weeks. B Plasma BNP content (ng/L). C Cardiac function indexes LVEF and LVFS of rats were measured with echocardiography. D H&E and Masson’s trichrome staining of the infarcted area of heart (scale bar = 1 mm, and for the zoom, scale bar = 0.5 mm). Three views were randomly selected from each slice (n = 6 for each group) and the blue collagen area of each slice was quantitatively analyzed using ImageJ software. The average blue collagen area of the model group was calibrated to a value ‘one’, and the remaining groups were analyzed relative to the model group. E TUNEL staining of the infarcted area of heart (scale bar = 20 μm). Three views were randomly selected from each slice (n = 6 for each group) and fluorescence intensity of each slice was quantitatively analyzed using ImageJ software. The average fluorescence intensity of the model group was calibrated to a value ‘one’, and the remaining groups were analyzed relative to the model group. F Immunohistochemistry of the infarcted area of heart (scale bar = 50 μm) Three views were randomly selected from each slice (n = 6 for each group) and the positive area of each slice was quantitatively analyzed using ImageJ software. The average positive area of the model group was calibrated to a value ‘one’, and the remaining groups were analyzed relative to the model group. G Body weight of ventricular remodeling rats after LQF, BNZ or vehicle treatment and sham rats were recorded every week during the intervention of the drug. All experimental data are expressed as mean ± standard deviation, ### p < 0.001 vs Sham, ** p < 0.01, *** p < 0.001, ns (not significant) compared with indicated group